Nanobiotix to Participate in Investor Conferences in November
Nanobiotix (NBTX) announced that management will participate in investor conferences in London on November 16 and 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nanobiotix (NBTX) announced that management will participate in investor conferences in London on November 16 and 17, 2026.
Chief Executive Officer Laurent Levy and Chief Financial Officer Arnd Christ will present at the Jefferies Global Healthcare Conference on November 16 at 8:30am ET / 1:30pm GMT. Management will also participate in the UBS Global Biopharma Conference on November 17.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November:
Jefferies Global Healthcare Conference in London
Date: Monday, November 16, 2026
Presentation Time: 8:30am ET / 1:30pm GMT
Location: London (UK)
Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer
UBS Global Biopharma Conference
Date: Tuesday, November 17, 2026
Location: London (UK)
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com | |
Attachment
